Back to Pazopanib

Pazopanib

Showing 3 study arms with grade ≥3 adverse event data (treatment-related and RT-related). Click a column header to sort.

Note on patient counts: some articles reported only percentages rather than absolute numbers. Where this occurred, the number of patients — including those with grade ≥3 adverse events — was derived by applying the reported percentage to the total arm size, which may produce a non-integer value. These figures have been rounded to the nearest integer for display.

1st Author⇅	Year⇅	Study Type⇅	Title⇅	DOI⇅	clinical trial number⇅	number of patients⇅	median/mean age⇅	tumor type⇅	treatment setting⇅	drug group⇅	drug name⇅	if other, please specify⇅	number of SBRT courses⇅	intracranial / extracranial⇅	treated site⇅	If other treated site, please specify⇅	median/mean total RT dose [Gy]⇅	minimum total RT dose [Gy]⇅	maximum total RT dose [Gy]⇅	median/mean number of fractions⇅	minimum number of fractions⇅	maximum number of fractions⇅	median/mean dose per fraction [Gy]⇅	minimum dose per fraction [Gy]⇅	maximum dose per fraction [Gy]⇅	toxicity type⇅	patients with acute G>=3 toxicity⇅	patients with late G>=3 toxicity⇅	patients with G>=3 toxicity, timing unspecified⇅	G>=3 AEs⇅	patients with G>=3 AEs⇅	details on G>=3 toxicity⇅	details on G>=3 toxicity in RT field⇅
Looman et al.	2026	Prospective	Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy	10.1001/jamanetworkopen.2025.53809	—	1	62	Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other	oligometastatic, metastatic	Multi-target TKI	Pazopanib	—	Missing	extra-cranial	other	Extremities	—	—	—	Missing	1	10	—	—	—	RT-related	—	—	0	—	—	—	—
Gebbia et al.	2020	Retrospective	Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World	10.21873/anticanres.14730	—	28	64	Kidney cancer	oligometastatic, metastatic	Multi-target TKI	Pazopanib	—	Missing	both	brain, lung, liver, bone, LN unspecified, other	kidney, skin	Missing	21.0	50.0	Missing	Missing	Missing	Missing	Missing	Missing	Treatment-rel.	—	—	7	any G3-4: 7 AEs	any G3-4: unknown pts	any G3-4: Hypertension, diarrhea, anemia, liver, pneumonitis	unknown
De Wolf et al.	2017	Prospective	Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial	10.1186/s13014-017-0893-x	NCT02334709	13	66	Kidney cancer	metastatic	Multi-target TKI	Pazopanib	—	13	extra-cranial	lung, liver, bone, LN unspecified, other	soft tissue, pancreas	30	24.0	36.0	3	3	3	10	8	12	Treatment-rel.	—	—	5	any G3-4: 6 AEs	any G3-4: 5 pts	any G3-4: hypoglycemie, increased ALT and increased AST, hypertension	/